Publications by authors named "S Delstanche"
Article Synopsis
- - International guidelines for myasthenia gravis (MG) exist, but a group of Belgian experts provides tailored recommendations specifically for managing MG in Belgium, focusing on both generalized (gMG) and ocular myasthenia gravis (oMG).
- - Treatment strategies are based on the efficacy of different therapies, their approval and reimbursement status in Belgium, everyday clinical practices, and the authors' personal experiences, reflecting the latest knowledge as of February 2024.
- - The publication also covers important factors for MG management, including handling comorbidities, avoiding drugs that worsen symptoms, considerations for pregnant patients, vaccination, and a forward-looking perspective on potential new treatments in the future.
The objective of the study was to assess the cost-effectiveness of real-world spinal muscular atrophy newborn screening followed by treatment. We modeled the lifetime cost-effectiveness of the spinal muscular atrophy newborn screening followed by treatment (screening) compared to treatment without screening (no screening) from the Belgian healthcare perspective. Real-world data, including quality of life, costs, and motor development data, were collected on 12 patients identified by screening and 43 patients identified by their symptoms.
View Article and Find Full Text PDFIntroduction: Hereditary transthyretin-mediated (hATTR) amyloidosis, a genetic disease caused by mutations in the transthyretin gene, leads to progressive sensory and autonomic neuropathy and/or cardiomyopathy and is associated with renal and ophthalmologic manifestations and a poor prognosis.
Methods: This is a retrospective study based on data collected from the medical records of patients with hATTR amyloidosis treated with patisiran between 01 July 2018 and 01 February 2021. Six Belgian neuromuscular reference centers participated, covering all patisiran-treated hATTR amyloidosis patients at the study time.
Amyotrophic lateral sclerosis (ALS) is an incurable disease characterized by muscle atrophy leading to complete paralysis. Once diagnosed, the average life expectancy is three to five years. In this context, palliative and end-of-life care are essential, as well as the development of cognitive and/or psychological therapies to improve the quality of life of patients.
View Article and Find Full Text PDFPurpose: Electrical stimulation of the sub-thalamic nucleus (STN-DBS) is well established to alleviate motor fluctuations in advanced Parkinson's disease but little is known about its very long-term efficacy.
Methods: We followed over 12 years 15 parkinsonian patients having undergone STN-DBS and compared them to a matched group of 14 patients with best medical drug therapy. All had been considered as good candidates for surgery.